Preclinical / early human

TB-500

Also known as: Thymosin Beta-4 fragment, TB4 fragment, TB-500 (synthetic)

Synthetic peptide fragment related to Thymosin Beta-4 (actin-binding regulatory protein)

Overview

TB-500 is a synthetic peptide associated with the actin-binding protein Thymosin Beta-4. In animal and cell studies it has been linked to cell migration, angiogenesis, and tissue repair, and it is marketed for wound healing and muscle/tendon recovery. As with BPC-157, robust human efficacy data is lacking — there are no completed large, controlled human trials supporting the marketed recovery claims. It is frequently stacked with BPC-157 in 'recovery' protocols, but that combination has not been validated in controlled human research. Claims should be treated as preliminary.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

Wound healing and tissue repair (marketed claim; primarily animal evidence)
Muscle and tendon recovery (marketed claim; unproven in controlled human trials)
Systemic recovery support (marketed claim; unproven)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

Subjective — healing/recovery and pain scores for a tracked injury
Whoop — recovery score and HRV trend
Labs — hs-CRP if monitored by a clinician
Range of motion / function for a rehabbed injury
Sleep quality — Whoop trends

Sources & References

Quick Reference

Class: Synthetic peptide fragment related to Thymosin Beta-4 (actin-binding regulatory protein)
Evidence Level: Preclinical / early human
Reported Uses: 3 listed
Tracking Metrics: 5 suggested
Citations: 3 sources

Safety & Legal Notes

NOT FDA-approved for human use. Like BPC-157, TB-500 was part of the batch of peptides whose Category 2 compounding nominations were withdrawn in 2026 (off Category 2 effective April 23, 2026) and slated for FDA Pharmacy Compounding Advisory Committee review in July 2026 — but this is NOT approval, and it was not a legally compoundable or OTC human drug at the time of writing. Most supply is sold as 'research use only.' EXPLICITLY PROHIBITED in sport: Thymosin Beta-4 / TB-500 was added to the WADA Prohibited List (Section S2) and remains banned. Long-term human safety is not established. Consult a licensed clinician.

Track your protocol in Protocolens

Connect your InBody, Whoop, smart scale, and nutrition data. See your Overlay — all metrics, one clear read.

Get started free →

← All entries

Educational Disclaimer

EDUCATIONAL INFORMATION ONLY — NOT MEDICAL ADVICE. The information in this dataset is compiled from published research, regulatory filings, and reputable secondary sources for educational purposes. It does not constitute medical, legal, or professional advice and is not a substitute for consultation with a licensed healthcare provider. Many compounds listed here are NOT approved by the U.S. Food and Drug Administration (FDA) for human use; some are sold only as research chemicals, some are available only via compounding pharmacies with a prescription, and many are prohibited in competitive sport under the World Anti-Doping Agency (WADA) Prohibited List. Regulatory status changes frequently — the 2026 FDA compounding reclassification is an active, evolving situation and reclassification is NOT the same as FDA approval. Individual results vary. Always consult a qualified, licensed healthcare provider before starting, stopping, or modifying any peptide, supplement, or health protocol. Peptide OS is a personal data-tracking tool and an educational publisher; it does not sell, prescribe, dispense, or facilitate the sale of any drug or peptide.